You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,915,225

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,915,225

Title:	Soluble tumor necrosis factor receptor treatment of medical disorders
Abstract:	The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF.alpha. by administering a TNF.alpha. antagonist, such as recombinant TNFR:Fc.
Inventor(s):	Finck; Barbara K (Mercer Island, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/394,962
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,915,225
Patent Claims:	1. A method for treating a patient having psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc, wherein the patient attains at least fifty percent improvement in PASI score. 2. The method of claim 1, wherein the dose of TNFR:Fc administered is either 50 mg once per week or 25 mg twice per week. 3. The method of claim 1, wherein the dose of TNFR:Fc administered is 50 mg twice per week. 4. The method of claim 1, wherein the TNFR:Fc is administered by subcutaneous injection. 5. The method of claim 1, wherein (a) a dose of 50 mg of TNFR:Fc is administered two times per week for at least two months and then (b) TNFR:Fc is administered at a reduced dose or at a reduced frequency. 6. The method of claim 5, wherein the administration of (b) is at a dose 25 mg of TNFR:Fc twice per week. 7. The method of claim 5, wherein the administration of (b) is at a dose of 50 mg once per week. 8. The method of claim 5, wherein the TNFR:Fc is administered by subcutaneous injection. 9. The method of claim 1, wherein the patient exhibits at least seventy five percent improvement in PASI score after three months of treatment. 10. The method of claim 1, wherein a corticosteroid is administered concurrently. 11. The method of claim 1, wherein methotrexate is administered concurrently. 12. A method for treating a patient having psoriasis and psoriatic arthritis comprising administering to the patient a therapeutically effective dose of TNFR:Fc, wherein the patient attains at least fifty percent improvement in PASI score. 13. The method of claim 12, wherein the dose of TNFR:Fc administered is either 50 mg once per week or 25 mg twice per week. 14. The method of claim 12, wherein a corticosteroid is administered concurrently. 15. The method of claim 12, wherein methotrexate is administered concurrently. 16. A method for treating a patient having psoriasis comprising (a) administering to the patient TNFR:Fc subcutaneously at a dose of 50 mg twice per week for at least two months and then (b) administering TNFR:Fc subcutaneously at a dose of 50 mg once per week or at a dose of 25 mg twice per week. 17. The method of claim 1, wherein cyclosporine is administered concurrently. 18. The method of claim 1, wherein acitretin is administered concurrently. 19. The method of claim 1, wherein ultraviolet light B phototherapy or psoralen combined with ultraviolet light A (PUVA) phototherapy is administered concurrently. 20. The method of claim 16, wherein the patient attains at least fifty percent improvement in PASI score.

Details for Patent 7,915,225

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2019-04-19
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020	⤷ Try a Trial	2019-04-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,915,225

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Australia	4363200	⤷ Try a Trial
Australia	4533601	⤷ Try a Trial
Canada	2366785	⤷ Try a Trial
Canada	2416250	⤷ Try a Trial
European Patent Office	1171148	⤷ Try a Trial
European Patent Office	1259252	⤷ Try a Trial
United States of America	2001021380	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.